BCTXW (BriaCell Therapeutics) Total Assets: $27.07 Mil (As of Apr. 2026)


BCTXW BriaCell Therapeutics Corp BCTXW
23 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics Total Assets?

BriaCell Therapeutics BCTXW 23 Total Assets is $27.07 Mil as of Apr. 2026. GuruFocus rates BCTXW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

BriaCell Therapeutics's Total Assets for the quarter that ended in Apr. 2026 was $27.07 Mil.

During the past 12 months, BriaCell Therapeutics's average Total Assets Growth Rate was -24.60% per year. During the past 3 years, the average Total Assets Growth Rate was 37.70% per year. During the past 5 years, the average Total Assets Growth Rate was 64.50% per year. During the past 10 years, the average Total Assets Growth Rate was 79.30% per year.

During the past 13 years, BriaCell Therapeutics's highest 3-Year average Total Assets Growth Rate was 514.60%. The lowest was -86.80%. And the median was 108.60%.

Total Assets is connected with ROA %. BriaCell Therapeutics's annualized ROA % for the quarter that ended in Apr. 2026 was -94.49%. Total Assets is also linked to Revenue through Asset Turnover. BriaCell Therapeutics's Asset Turnover for the quarter that ended in Apr. 2026 was 0.00.

BriaCell Therapeutics  (NAS:BCTXW) Total Assets Explanation

Total Assets is connected with ROA %.

BriaCell Therapeutics's annualized ROA % for the quarter that ended in Apr. 2026 is

ROA %=Net Income (Q: Apr. 2026 )/( (Total Assets (Q: Jan. 2026 )+Total Assets (Q: Apr. 2026 ))/ count )
=-28.66/( (33.594+27.071)/ 2 )
=-28.66/30.3325
=-94.49 %

Note: The Net Income data used here is four times the quarterly (Apr. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BriaCell Therapeutics's Asset Turnover for the quarter that ended in Apr. 2026 is

Asset Turnover
=Revenue (Q: Apr. 2026 )/( (Total Assets (Q: Jan. 2026 )+Total Assets (Q: Apr. 2026 ))/ count )
=0/( (33.594+27.071)/ 2 )
=0/30.3325
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BriaCell Therapeutics Total Assets Related Terms

BriaCell Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics Total Assets Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.04 42.58 27.16 5.87 21.65

BriaCell Therapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.00 21.65 13.08 33.59 27.07
BCTXW
23GF Score
BriaCell Therapeutics Corp BCTXW
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BriaCell Therapeutics's Total Assets for the fiscal year that ended in Jul. 2025 is calculated as

Total Assets=Total Equity (A: Jul. 2025 )+Total Liabilities (A: Jul. 2025 )
=17.334+4.316
=21.65

BriaCell Therapeutics's Total Assets for the quarter that ended in Apr. 2026 is calculated as

Total Assets=Total Equity (Q: Apr. 2026 )+Total Liabilities (Q: Apr. 2026 )
=23.409+3.662
=27.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $27.07 Mil mean?
BriaCell Therapeutics (BCTXW) has a Total Assets of $27.07 Mil as of Apr. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on BriaCell Therapeutics and its competitors.
Is BriaCell Therapeutics' Total Assets too high?
BriaCell Therapeutics' current Total Assets is $27.07 Mil. Overall, BriaCell Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' Total Assets compare to VRTX and REGN?
BriaCell Therapeutics' Total Assets of $27.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on BriaCell Therapeutics and its competitors. BriaCell Therapeutics's current Total Assets is $27.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (BCTXW) has a current Total Assets of $27.07 Mil. The current Total Assets is $27.07 Mil. BriaCell Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For BriaCell Therapeutics (BCTXW), the current Total Assets is $27.07 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BriaCell Therapeutics Business Description

Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
23GF Score

Get the complete analysis for BCTXW

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price